본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Proceedings of the National Academy of Sciences of the United States of America v.114 no.4, 2017년, pp.740 - 745   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors

Xin, Gang (Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53213 ); Schauder, David M. ( ); Jing, Weiqing ( Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53213 ); Jiang, Aimin ( ); Joshi, Nikhil S. ( Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226 ); Johnson, Bryon ( ); Cui, Weiguo ( Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263 );
  • 초록  

    Significance Immunosuppressive tumor microenvironment, insufficient migration, and reduced effector function of tumor-specific T cells are the main hurdles that hamper the efficacy of immunotherapy in treating solid tumors. In this study, we combined the strength of adoptive cell transfer (ACT) and pathogen-based cancer vaccine and developed an innovative strategy, Reenergized ACT (ReACT), to treat solid tumors. ReACT uses a pathogen not only to break the immunosuppression, but also to drive the expansion and migration of tumor-specific T cells to the site of the tumor. With this combinatorial approach, we have demonstrated that ReACT enhances antitumor efficacy in comparison with either ACT or pathogen-based cancer vaccine alone in primary tumor eradication and offers long-term protection against reoccurrence in preclinical cancer models. Because of insufficient migration and antitumor function of transferred T cells, especially inside the immunosuppressive tumor microenvironment (TME), the efficacy of adoptive cell transfer (ACT) is much curtailed in treating solid tumors. To overcome these challenges, we sought to reenergize ACT (ReACT) with a pathogen-based cancer vaccine. To bridge ACT with a pathogen, we genetically engineered tumor-specific CD8 T cells in vitro with a second T-cell receptor (TCR) that recognizes a bacterial antigen. We then transferred these dual-specific T cells in combination with intratumoral bacteria injection to treat solid tumors in mice. The dual-specific CD8 T cells expanded vigorously, migrated to tumor sites, and robustly eradicated primary tumors. The mice cured from ReACT also developed immunological memory against tumor rechallenge. Mechanistically, we have found that this combined approach reverts the immunosuppressive TME and recruits CD8 T cells with an increased number and killing ability to the tumors.


  • 주제어

    adoptive cell transfer .   immunotherapy .   CD8 T cells .   Listeria .   melanoma.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기